A company specialising in novel treatments for Parkinson’s disease is the first to be spun out of Merck Serono’s soon-to-close …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

